Amarin Corp Plc (AMRN)

[Chris2125]

"Looking forward, we believe Vascepa has enormous potential to drive the growth of our business. In Q1, on the heels of announcing data exclusivity for Vascepa, we increased our peak-year sales forecast for the product to C$200-300 million, from C$150-250 million, reflecting our growing confidence in its potential to positively change the lives of many Canadians. Supported by the significant data results from the landmark REDUCE-IT Trial, the endorsement from many major medical societies around the world and the prevalence of cardiovascular disease in Canada, we believe as strongly in Vascepa's long-term potential today as we have at any time."